Intravenous administration of the incretin hormones in patients suffering from type 2 diabetes causes the increase in early-phase insulin secretion in response to a meal, but only GLP-1 is able to stimulate insulin secretion in late phase [2]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.